The Food and Drug Administration has authorized the use of convalescent plasma in Arkansas as an experimental treatment for COVID-19 with the University of Arkansas for Medical Sciences (UAMS) as the expanded access treatment program sponsor.
With the authorization, UAMS Medical Center is able to use the treatment now without applying for FDA approval for every patient. Other healthcare providers in the state can also work through the UAMS Arkansas Expanded Access COVID-19 Convalescent Plasma Treatment Program to use the treatment.
Samar Qedan, APRN, recently joined Washington Regional Walker Heart Cardiovascular Clinic where she provides care to patients with acute and chronic cardiovascular conditions.